MA02.06 Phase 1b Study of Pelcitoclax (APG-1252) in Combination With Osimertinib in Patients With EGFR TKI-Resistant NSCLC

Third-generation tyrosine kinase inhibitor (TKI) osimertinib is standard of care for patients with EGFR-mutant non-small cell lung cancer (NSCLC), although resistance almost inevitably develops. Pelcitoclax (APG-1252) is a dual BCL-2/BCL-xL inhibitor which exhibits synergistic anti-tumor effects with osimertinib in preclinical models of EGFR-mutant NSCLC.